ClinicalTrials.gg

Program

cafelkibart

Also written as “LM-108”, “LM-108 in combination with Toripalimab” and “LM-108 injection”.

In Sino Biopharmaceutical's pipeline, CCR8单抗. Its studies are mostly in Pancreatic Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 3, since Jan 7, 20267 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical75 open or runningphase 3since Jan 7, 2026Dec 15, 2021Dec 2027phase 2 · NCT06821503
  • Named in Sino Biopharmaceutical’s own pipeline as LM-108, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2021First study: phase 2 study in Advanced Solid TumorFirst studyNCT05199753 · 78 enrolled · Australia
  2. Feb 14, 2022Phase 2 study in Advanced Solid TumorNCT05255484 · 24 enrolled · United States
  3. Aug 24, 2022Phase 2 study in Advanced Solid TumorNCT05518045 · 392 enrolled · China
  4. Jan 21, 2025Phase 2 study in Advanced Pancreatic CancerNCT06821503 · 72 planned · China
  5. Feb 9, 20252 phase 2 studies in Advanced Solid TumorNCT06825494, NCT06873854
  6. Jan 7, 2026Phase 3 study in Locally Advanced or Metastatic GC and GCJ AdenocarcinomaPhase 3 reachedNCT07362186 · 400 planned · China

Ahead

  1. Dec 2027Primary completion: phase 2 study in Advanced Pancreatic CancerNCT06821503
  2. Jan 26, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT06873854
  3. Aug 17, 2028Primary completion: phase 3 study in Locally Advanced or Metastatic GC and GCJ AdenocarcinomaNCT07362186

TargetBeta

“CCR8单抗”the company's pipeline, read by Claude · source
“A monoclonal antibody against C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule

Other programs on CCR8

ProgramCompanyFurthest phaseStudies
CCR8 Inhibitor IPG7236rulenanjing-immunophage-biotech-co-ltdphase 23
denikitugruleGilead Sciencesphase 23
imzokitugBristol-Myers Squibbphase 22
Anti-CCR8 Antibody-drug Conjugate TAK-188ruleTakedaphase 21
Anti-CCR8 Monoclonal Antibody HC006rulehc-biopharma-incphase 12
azirkitugAbbViephase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07362186Locally Advanced or Metastatic GC and GCJ Adenocarcinoma · China3RecruitingAug 17, 2028400
NCT06873854Advanced Solid Tumor · China2Not yet recruitingJan 26, 202884
NCT06825494Advanced Solid Tumor · China2RecruitingMar 2026194
NCT06821503Advanced Pancreatic Cancer · China2RecruitingDec 202772
NCT05518045Advanced Solid Tumor · China2Active, not recruitingOct 31, 2026392
NCT05255484Advanced Solid Tumor · United States2TerminatedOct 6, 202324
NCT05199753Advanced Solid Tumor · Australia2CompletedDec 31, 202478

How it is read

Names in the registry

  • “LM-108”, 4 entries
  • “LM-108 in combination with Toripalimab”, 1 entry
  • “LM-108 injection”, 1 entry
  • “LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine”, 1 entry
  • “LM-108 injection 10mg/kg +penpulimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.